A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial

by Jeffrey R. Curtis, Christopher Herrem, ’Matladi N. Ndlovu, Cathy O’Brien, Yusuf Yazici
Published 2017-09-01

Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment

by Jeffrey R. Curtis, Kevin Winthrop, Cathy O’Brien, Matladi N. Ndlovu, Marc de Longueville, Boulos Haraoui
Published 2017-12-01